Enterprise Value
7.218B
Cash
1.474B
Avg Qtr Burn
-69.71M
Short % of Float
6.85%
Insider Ownership
5.49%
Institutional Own.
92.79%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
KarXT (M1/M4 muscarinic agonist) Details Mental health, Schizophrenia | NDA Submission | |
KarXT (M1/M4 muscarinic agonist) Details Mental health, Schizophrenia | Phase 3 Data readout | |
KarXT (M1/M4 muscarinic agonist) Details Mental health, Schizophrenia, Alzheimer's disease | Phase 3 Initiation | |
KarXT (M1/M4 muscarinic agonist) Details Mental health, Schizophrenia | Phase 1b Data readout |